AtriCure Inc. (NASDAQ:ATRC) CEO Sells $1,075,000.00 in Stock

Share on StockTwits

AtriCure Inc. (NASDAQ:ATRC) CEO Michael H. Carrel sold 25,000 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $43.00, for a total transaction of $1,075,000.00. Following the completion of the sale, the chief executive officer now owns 651,490 shares of the company’s stock, valued at $28,014,070. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Shares of NASDAQ ATRC opened at $43.84 on Friday. The company has a 50-day moving average price of $36.83 and a 200-day moving average price of $30.16. AtriCure Inc. has a 1 year low of $22.57 and a 1 year high of $44.32. The company has a current ratio of 3.11, a quick ratio of 2.49 and a debt-to-equity ratio of 0.29.

A number of research firms have commented on ATRC. BTIG Research began coverage on shares of AtriCure in a report on Thursday, February 6th. They issued a “buy” rating and a $42.00 price target for the company. BidaskClub upgraded shares of AtriCure from a “buy” rating to a “strong-buy” rating in a report on Friday, January 3rd. ValuEngine cut shares of AtriCure from a “buy” rating to a “hold” rating in a report on Tuesday, January 28th. Zacks Investment Research cut shares of AtriCure from a “hold” rating to a “sell” rating in a report on Tuesday, December 31st. Finally, Needham & Company LLC restated a “buy” rating and issued a $48.00 price target (up from $39.00) on shares of AtriCure in a report on Friday, January 24th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $38.86.

Several hedge funds and other institutional investors have recently modified their holdings of ATRC. Champlain Investment Partners LLC grew its holdings in shares of AtriCure by 85.0% during the fourth quarter. Champlain Investment Partners LLC now owns 1,249,640 shares of the medical device company’s stock valued at $40,626,000 after buying an additional 574,205 shares during the last quarter. GW&K Investment Management LLC grew its holdings in shares of AtriCure by 18.3% during the fourth quarter. GW&K Investment Management LLC now owns 1,170,079 shares of the medical device company’s stock valued at $38,040,000 after buying an additional 181,092 shares during the last quarter. Tamarack Advisers LP grew its holdings in shares of AtriCure by 25.9% during the third quarter. Tamarack Advisers LP now owns 850,000 shares of the medical device company’s stock valued at $21,199,000 after buying an additional 175,000 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in shares of AtriCure by 142.9% during the fourth quarter. Point72 Asset Management L.P. now owns 261,128 shares of the medical device company’s stock valued at $8,489,000 after buying an additional 153,606 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of AtriCure by 55.8% during the fourth quarter. Renaissance Technologies LLC now owns 323,200 shares of the medical device company’s stock valued at $10,507,000 after buying an additional 115,700 shares during the last quarter. Hedge funds and other institutional investors own 88.08% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy.

Further Reading: Which market index is the best?

Insider Buying and Selling by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.